- Home
- QNCX vs CELU Comparison
QNCX vs CELU Comparison
Compare QNCX & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | CELU |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 17.3M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | QNCX | CELU |
|---|---|---|
| Price | $29.44 | $1.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.2K | ★ 10.8M |
| Earning Date | 04-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $26,550,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.08 | $0.56 |
| 52 Week High | $35.41 | $2.55 |
Technical Indicators
Market Signals| Indicator | QNCX | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 56.23 |
| Support Level | $0.82 | $1.13 |
| Resistance Level | $35.38 | $2.55 |
| Average True Range (ATR) | 2.07 | 0.36 |
| MACD | -1.04 | 0.00 |
| Stochastic Oscillator | 4.41 | 38.99 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.